I put float around 60m at most if new OS went in public. AS was just raised so should keep that in mind.
Plan of Operations
We anticipate that if our clinical studies on our ED stem cell treatment are successful, we can commence marketing kits for the treatment in 2018. For the next 12 months our plan of operations is to complete these clinical trials and commence marketing of the kits. We estimate the costs to complete the clinical trials will be approximately $500,000, excluding overhead and other costs associated with maintaining our company structure. We believe that our current cash on hand would meet our cash flow requirements for only a few more months. If we are unable to obtain further financing, we may seek alternative sources of funding or revise our business plan. We currently have no alternative sources for funding.
Safety and Efficacy of Caverstem TM Procedure
On October 18, 2017 we announced the completion of the safety data analysis on 20 patients in our erectile dysfunction clinical trial. Based on establishment of safety of the CaverStem TM procedure in a formal university-based clinical trial, and independent confirmation of efficacy in a European clinical trial we launched commercialization for the Caverstem TM procedure.
(January 31, 2018 – Phoenix, AZ) Creative Medical Technology Holdings Inc. (OTCQB ticker symbol CELZ) announced today the continued positive response and recruitment of physicians for its patented and clinically tested Caverstem™ procedure for the treatment of erectile dysfunction using the patient’s own bone marrow derived stem cells.
“Since commercialization of our Caverstem™ procedure began in December 2017, we’re pleased that our early results in bringing in experienced medical doctors in our initial area of sales in the Southwest United States has been very positive. Recruitment of medical doctors in Los Angeles, Orange County, San Diego and Las Vegas NV is just the start of what we believe will be a rapid growth as we expand into other areas of the country” said Timothy Warbington, CEO of Creative Medical Technology Holdings, Inc.
“Patient understanding and interest in our stem cell technology has also been positive. The physicians involved with the Caverstem™ procedure are treating patients and as the patient outreach is expanded we are excited by the ongoing and increased growth in the number of patient’s seeking our treatment.”
Approximately 30% of the 30,000,000 patients suffering from erectile dysfunction do not respond to drugs like Viagra, Cialis and Levitra, in part due to an underlying degeneration of the biological machinery needed to achieve erections. The Caverstem™ procedure is a natural alternative for many of these patients.
“There is much excitement about stem cells revolutionizing many aspects of medicine. I am enthusiastic to be treating my patients using this cutting edge procedure,” Stated by Dr. Alexander Gershman. “Numerous publications and a recent clinical trial at the Los Angeles Biomedical Institute at Harbor – UCLA Hospital in Torrance, CA, support the safety and feasibility of the Caverstem™ procedure. The biological basis of the bone marrow based treatment is that in patients with drug non-responsive erectile dysfunction, there is a deficit in function of smooth muscle and blood vessel cells. By administering the patient’s own stem cells we aim to rebuild these damaged tissues, and thereby restore erectile function.”
“We are pleased that after several years of development and testing we are now realizing the overwhelming acceptance of our Caverstem™ procedure by highly credible physicians and their patients.” Said Thomas Ichim PhD, co-inventor of the Caverstem™ procedure and Director of Creative Medical Technology Holdings Inc.
Recent CELZ News
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/04/2024 09:01:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/23/2024 08:23:39 PM
- Creative Medical Technology Holdings Announces $1.85 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules • GlobeNewswire Inc. • 10/23/2024 12:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 10/16/2024 04:15:14 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 10/04/2024 08:45:55 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 08:45:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/25/2024 08:10:25 PM
- Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program • GlobeNewswire Inc. • 07/24/2024 01:00:39 PM
- Creative Medical Technology Holdings Provides Corporate Update • GlobeNewswire Inc. • 07/10/2024 12:30:00 PM
- Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin • GlobeNewswire Inc. • 06/24/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:02:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:45:39 PM
- Creative Medical Technology Holdings Provides Corporate Update • Business Wire • 03/27/2024 01:00:00 PM
- Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access • Business Wire • 03/07/2024 02:15:00 PM
- Biotech Finds Mid-Week Success Following FDA Announcement • AllPennyStocks.com • 03/06/2024 09:10:00 PM
- Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy • Business Wire • 03/06/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2023 09:05:37 PM
- Creative Medical Technology Holdings Provides Corporate Update • PR Newswire (US) • 11/15/2023 01:00:00 PM
VAYK Confirms Insider Buying at Open Market • VAYK • Nov 5, 2024 10:40 AM
Rainmaker Worldwide Inc. Announces Strategic Partnership Between Miranda Water Technologies and Fleming College • RAKR • Nov 4, 2024 12:03 PM
North Bay Resources Announces Assays up to 9.5% Copper at Murex Copper Project, British Columbia • NBRI • Nov 4, 2024 9:00 AM
Rainmaker Worldwide Inc. to Assume Direct, Non-Dealer Sales of Miranda Water Technologies in U.S. and Mexico in First Quarter of 2025 • RAKR • Nov 4, 2024 8:31 AM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM